PeptiDex research reference visual for Gonadorelin Acetate
Hormonal & Sexual Health

Gonadorelin Acetate

GnRH analog

A synthetic decapeptide form of gonadotropin-releasing hormone (GnRH) referenced in reproductive-endocrinology research.

Also referenced as: GnRH, LHRH

10 aat½ ~2-10 min (distribution); ~10-40 min (terminal)
For research and educational purposes only. This page is a factual research reference, not medical advice. Any dosing figures shown are amounts reported in the research literature, provided for educational context — not instructions or recommendations for human use.

Overview

Gonadorelin is a synthetic form of the endogenous decapeptide gonadotropin-releasing hormone (GnRH, also called LHRH). Its acetate salt is used clinically in reproductive endocrinology.

At a glance

ClassGnRH analog
CategoryHormonal & Sexual Health
SequencepGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
Chain length10 amino acids
Molecular weight~1182 g/mol
Half-life~2-10 min (distribution); ~10-40 min (terminal)
Typical formLyophilized powder
AliasesGnRH, LHRH
Use designationResearch / in-vitro only
Regulatory statusGonadorelin is an approved drug used in endocrine and fertility medicine (diagnostic and therapeutic). Educational content only; no dosing or usage guidance; not medical advice.

What Gonadorelin Acetate does

Gonadorelin is synthetic GnRH — a decapeptide identical to the native gonadotropin-releasing hormone made by the hypothalamus. Its defining action is to bind GnRH receptors on anterior-pituitary gonadotroph cells and provoke the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Because it is the natural pituitary secretagogue, it works one step below kisspeptin/GnRH-neuron signaling and one step above the gonads, and it is the pituitary itself that it acts on.

The crucial pharmacologic feature of gonadorelin is that its effect depends entirely on how it is delivered. Delivered in short, physiologically timed pulses (classically via a programmable pump), it mimics endogenous GnRH and sustains normal, cyclical LH/FSH secretion; the released LH then drives Leydig-cell testosterone production in men and follicular/ovarian steroidogenesis and ovulation in women, while FSH supports Sertoli-cell function and spermatogenesis or follicle growth. Delivered continuously or too frequently, by contrast, the same molecule desensitizes and downregulates the GnRH receptor and suppresses gonadotropin output — the paradox that underlies GnRH-agonist therapy.

Gonadorelin has a very short half-life (minutes), reflecting rapid enzymatic breakdown, which is exactly why native-style pulsatility is achievable and why it is used clinically both as a diagnostic agent (a GnRH-stimulation test of pituitary reserve) and, in pulsatile form, to induce puberty, fertility, or ovulation in hypothalamic hypogonadism. Its actions on the pituitary-gonadal axis are well established in humans.

Effects reported in research

  • Binds pituitary gonadotroph GnRH receptors and triggers release of LH and FSH (established human physiology).
  • When given in physiologic pulses, restores cyclical gonadotropin secretion and can induce ovulation or spermatogenesis in hypothalamic hypogonadism (human clinical use).
  • Downstream LH stimulates Leydig-cell testosterone synthesis in men (human).
  • Downstream FSH supports Sertoli-cell function/spermatogenesis in men and follicular development in women (human).
  • Used as a diagnostic GnRH-stimulation test to assess pituitary gonadotropin reserve (human clinical use).
  • Continuous rather than pulsatile exposure desensitizes and downregulates the GnRH receptor, paradoxically suppressing LH/FSH (established mechanism).
  • Has a very short plasma half-life (minutes) due to rapid enzymatic degradation, requiring frequent or pump-based dosing (human pharmacokinetics).

Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.

Mechanism of action

Gonadorelin is structurally identical to native GnRH and binds GnRH receptors on pituitary gonadotrophs, stimulating secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Because it is the native decapeptide with a short half-life, pulsatile administration mimics physiological GnRH release, whereas continuous exposure can downregulate the receptor. It is used diagnostically and to stimulate the hypothalamic-pituitary-gonadal axis.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which Gonadorelin Acetate appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Pituitary-gonadotropin axis stimulation and testing (medical use)Reproductive endocrinology and fertility (medical use)GnRH receptor pharmacologyHypothalamic-pituitary axis diagnostics

Key characteristics

  • Synthetic peptide identical to native GnRH (LHRH) decapeptide.
  • Stimulates pituitary LH and FSH secretion via GnRH receptors.
  • Short half-life; pulsatile delivery mimics physiological signaling.
  • Used diagnostically and therapeutically in endocrine/fertility medicine.
  • Distinct from long-acting superagonists like triptorelin.

Reported research dosing reference only

Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Gonadorelin Acetate is a research compound.

Reference figures only. Research literature describes low-microgram subcutaneous administration, often as an intermittent HPG-axis stimulus.

  • Axis-support research reference: ~50-100 mcg subcutaneous, 2-3 times weekly
  • Hypogonadotropic models: ~100-250 mcg, 2-3 times weekly (referenced)
  • Pulsatile pump protocols: micro-boluses every ~90-120 min
Reported frequencyIntermittent/pulsatile; continuous exposure suppresses rather than stimulates the axis
ReconstitutionLyophilized peptide reconstituted with bacteriostatic/sterile water; refrigerate after reconstitution

Very short half-life (~2-40 min) is central to protocol design; pulsatile timing matters more than total dose. Reference figures for research context only.

How it compares

Gonadorelin is the native GnRH decapeptide with a short half-life, contrasting with triptorelin, a modified long-acting GnRH superagonist that produces sustained receptor downregulation.

Commonly studied alongside

Compounds frequently researched together with Gonadorelin Acetate in the literature. Cross-referenced for research context — not a usage or combination recommendation.

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

  • Avoid repeated freeze-thaw cycles
  • Verify supplier lot and Certificate of Analysis
  • Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

Gonadorelin Acetate sits in the Hormonal & Sexual Health area of the PeptiDex library.

Research Supplier Listing

Where researchers source Gonadorelin Acetate

For researchers studying Gonadorelin Acetate, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.

Explore Research Suppliers →

PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.

Frequently asked questions

What is gonadorelin?

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), a decapeptide identical to the native hypothalamic sequence. It agonizes the pituitary GnRH receptor to trigger release of LH and FSH, making it a core research tool for probing the HPG axis.

Why must gonadorelin be given in pulses?

The GnRH receptor responds to pulsatile stimulation but desensitizes under continuous exposure, which paradoxically suppresses LH/FSH. Research protocols therefore administer gonadorelin intermittently (often modeling ~90-120 minute pulses) to sustain a gonadotropin response rather than shut it down.

How does gonadorelin differ from triptorelin?

Gonadorelin is native GnRH with a very short half-life, so it behaves as a pulsatile stimulus. Triptorelin is a modified super-agonist (D-Trp at position 6) with far greater potency and duration, which after an initial flare causes sustained receptor desensitization and downstream suppression.

What does gonadorelin's short half-life imply for research?

With a distribution half-life of only ~2-10 minutes and terminal half-life of ~10-40 minutes, gonadorelin is cleared rapidly by endopeptidases. This short duration is why it is used for pulsatile stimulation and acute pituitary-response (stimulation) testing rather than sustained dosing.

How does gonadorelin compare to HCG?

Gonadorelin drives the pituitary to release the body's own LH/FSH, whereas HCG mimics LH directly at the gonad and bypasses the pituitary. They are studied as complementary probes of upstream versus downstream HPG-axis function.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

Related compounds in Hormonal & Sexual Health

Further reading